Wall Street analysts expect Aduro BioTech Inc (NASDAQ:ADRO) to report sales of $4.73 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Aduro BioTech’s earnings. The highest sales estimate is $5.80 million and the lowest is $3.50 million. Aduro BioTech posted sales of $2.76 million during the same quarter last year, which would indicate a positive year over year growth rate of 71.4%. The firm is expected to announce its next earnings report on Wednesday, February 26th.
According to Zacks, analysts expect that Aduro BioTech will report full year sales of $17.98 million for the current year, with estimates ranging from $15.83 million to $19.40 million. For the next financial year, analysts forecast that the business will report sales of $18.93 million, with estimates ranging from $14.00 million to $25.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that cover Aduro BioTech.
Aduro BioTech (NASDAQ:ADRO) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.03. The business had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $4.55 million. Aduro BioTech had a negative net margin of 544.94% and a negative return on equity of 78.64%.
A number of hedge funds have recently made changes to their positions in ADRO. Metropolitan Life Insurance Co NY purchased a new stake in Aduro BioTech in the 1st quarter worth $99,000. DekaBank Deutsche Girozentrale raised its position in shares of Aduro BioTech by 63.6% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 58,400 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 22,700 shares in the last quarter. Candriam Luxembourg S.C.A. raised its position in shares of Aduro BioTech by 32.0% during the 2nd quarter. Candriam Luxembourg S.C.A. now owns 239,000 shares of the biotechnology company’s stock valued at $366,000 after buying an additional 58,000 shares in the last quarter. Swiss National Bank raised its position in shares of Aduro BioTech by 21.4% during the 2nd quarter. Swiss National Bank now owns 89,000 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 15,700 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in shares of Aduro BioTech by 62.9% during the 2nd quarter. Wells Fargo & Company MN now owns 52,531 shares of the biotechnology company’s stock valued at $81,000 after buying an additional 20,286 shares in the last quarter. Institutional investors and hedge funds own 39.58% of the company’s stock.
About Aduro BioTech
Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.
Further Reading: Stock Symbols, CUSIP and Other Stock Identifiers
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.